# US 2013/0157880 A1 · Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157880 A1
- Document ID: US20130157880A1
- Status: Published application
- Kind: A1
- Application number: 13/521,535
- Filed: 2011-01-20
- Published: 2013-06-20
- Earliest claimed: 2010-01-21
- Assignees: Sanofi
- Inventors: Mathias Gebauer; Martin Michaelis; Danping Ding-Pfennigdorff; Anke M. Schulte; Daniel Ziemek; Christiane Metz-Weidmann
- Web page: https://patentgrep.com/patent/US20130157880A1

## CPC

- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- G01N 33/6893: {related to diseases not provided for elsewhere}
- C12Q 2600/136: Screening for pharmacological compounds
- C12Q 2600/158: Expression markers
- G01N 2800/2842: Pain, e.g. neuropathic pain, psychogenic pain
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to a method of identifying a compound involved in pain, the use of Car3 nucleic acid or Car3 protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.

## Claims

### Claim 1

A method of identifying a compound involved in pain, the method comprising the steps of:
a) providing a test system comprising Car3 nucleic acid or Car3 protein or a functionally active variant of Car3 protein,
b) contacting the test system with a test compound, and
c) determining the effect of the test compound on the test system,
wherein the test compound is identified as a compound involved in pain when a significant effect of the test compound on the test system relative to a control is detected.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1, wherein the compound involved in pain is a cellular compound which is part of the signal transduction pathway of the Car3 gene and/or the Car3 protein.

### Claim 4 (depends on 3)

The method of claim 3, wherein the compound involved in pain alters signal transduction upstream or downstream of the Car3 protein.

### Claim 5 (depends on 3)

The method of claim 3, wherein the compound involved in pain alters signal transduction upstream or downstream of the Car3 gene.

### Claim 6 (depends on 1)

The method of claim 1, wherein the compound involved in pain binds to a cellular compound which is part of the signal transduction pathway of the Car3 gene and/or the Car3 protein.

### Claim 7 (depends on 6)

The method of claim 6, wherein the compound involved in pain inhibits signal transduction upstream or downstream of the Car3 gene.

### Claim 8 (depends on 6)

The method of claim 6, wherein the compound involved in pain inhibits signal transduction upstream or downstream of the Car3 protein.

### Claim 9 (depends on 1)

The method of claim 1, wherein the test system is a cell.

### Claim 10 (depends on 1)

The method of claim 1, wherein the method is a high-through-put method.

### Claim 11 (depends on 1)

The method of claim 1, wherein the pain is neuropathic pain.

### Claim at position 12

12-14. (canceled)

### Claim 15

A method of diagnosing algesia, comprising the steps of
a) determining the level of expression of the Car3 gene in a subject's sample, and
b) identifying the subject as algesic if the level expression of the Car3 gene is increased in the subject's sample relative to a control sample.

### Claim 16 (depends on 5)

The method of claim 5, wherein the compound alters expression of the Car3 gene.

### Claim 17 (depends on 6)

The method of claim 6, wherein the compound involved in pain binds to the Car3 nucleic acid.

### Claim 18 (depends on 7)

The method of claim 7, wherein the compound involved in pain inhibits expression of the Car3 gene.

### Claim 19 (depends on 8)

The method of claim 8, wherein the compound involved in pain binds to the Car3 protein.
